HEADER TRANSFERASE 21-MAR-12 4ANQ TITLE STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH TITLE 2 CRIZOTINIB COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALK TYROSINE KINASE RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: KINASE, RESIDUES 1093-1411; COMPND 5 SYNONYM: ANAPLASTIC LYMPHOMA KINASE, CD246; COMPND 6 EC: 2.7.10.1; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PFASTBAC1 KEYWDS TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR M.MCTIGUE,Y.DENG,W.LIU,A.BROOUN REVDAT 4 20-DEC-23 4ANQ 1 REMARK REVDAT 3 08-MAY-19 4ANQ 1 REMARK REVDAT 2 19-MAR-14 4ANQ 1 JRNL ATOM REVDAT 1 27-MAR-13 4ANQ 0 JRNL AUTH Q.HUANG,T.W.JOHNSON,S.BAILEY,A.BROOUN,K.D.BUNKER,B.J.BURKE, JRNL AUTH 2 M.R.COLLINS,A.S.COOK,J.J.CUI,K.N.DACK,J.G.DEAL,Y.DENG, JRNL AUTH 3 D.DINH,L.D.ENGSTROM,M.HE,J.HOFFMAN,R.L.HOFFMAN,P.S.JOHNSON, JRNL AUTH 4 R.S.KANIA,H.LAM,J.L.LAM,P.T.LE,Q.LI,L.LINGARDO,W.LIU,M.W.LU, JRNL AUTH 5 M.MCTIGUE,C.L.PALMER,P.F.RICHARDSON,N.W.SACH,H.SHEN,T.SMEAL, JRNL AUTH 6 G.L.SMITH,A.E.STEWART,S.TIMOFEEVSKI,K.TSAPARIKOS,H.WANG, JRNL AUTH 7 H.ZHU,J.ZHU,H.Y.ZOU,M.P.EDWARDS JRNL TITL DESIGN OF POTENT AND SELECTIVE INHIBITORS TO OVERCOME JRNL TITL 2 CLINICAL ANAPLASTIC LYMPHOMA KINASE MUTATIONS RESISTANT TO JRNL TITL 3 CRIZOTINIB. JRNL REF J.MED.CHEM. V. 57 1170 2014 JRNL REFN ISSN 0022-2623 JRNL PMID 24432909 JRNL DOI 10.1021/JM401805H REMARK 2 REMARK 2 RESOLUTION. 1.76 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.76 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 52.31 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1173657.910 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.3 REMARK 3 NUMBER OF REFLECTIONS : 30753 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.201 REMARK 3 R VALUE (WORKING SET) : 0.201 REMARK 3 FREE R VALUE : 0.217 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT : 910 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.76 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.87 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 91.90 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 4596 REMARK 3 BIN R VALUE (WORKING SET) : 0.2530 REMARK 3 BIN FREE R VALUE : 0.2570 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 3.20 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 150 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.021 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2313 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 209 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 25.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.85000 REMARK 3 B22 (A**2) : -3.10000 REMARK 3 B33 (A**2) : 4.95000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.20 REMARK 3 ESD FROM SIGMAA (A) : 0.13 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.23 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.14 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.004 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 18.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.640 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.420 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.270 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.300 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.510 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.37 REMARK 3 BSOL : 50.06 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : VGH.PARAM REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : VGH.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4ANQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 21-MAR-12. REMARK 100 THE DEPOSITION ID IS D_1290051796. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-OCT-11 REMARK 200 TEMPERATURE (KELVIN) : 87 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30797 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.770 REMARK 200 RESOLUTION RANGE LOW (A) : 104.620 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.5 REMARK 200 DATA REDUNDANCY : 6.500 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 22.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.77 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : 6.80 REMARK 200 R MERGE FOR SHELL (I) : 0.44000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 4.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: PDB ENTRY 2XP2 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.80 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.18 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTALS WERE GROWN BY THE HANGING REMARK 280 DROP VAPOR DIFFUSION METHOD AT 13 DEGREES CELSIUS BY MIXING 2 REMARK 280 MICROLITERS OF PROTEIN SOLUTION WITH A RESERVOIR SOLUTION REMARK 280 CONTAINING: 18% (W/V) PEG 3350, 0.1 M TRIS PH 8.5, 0.2M LITHIUM REMARK 280 SULFATE, AND 0.1(W/V) BETA-OCTYLGLCOSIDE., VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.81300 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.30850 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.73650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.30850 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.81300 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.73650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLY 1269 TO ALA REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1070 REMARK 465 ALA A 1071 REMARK 465 HIS A 1072 REMARK 465 HIS A 1073 REMARK 465 HIS A 1074 REMARK 465 HIS A 1075 REMARK 465 HIS A 1076 REMARK 465 HIS A 1077 REMARK 465 ASP A 1078 REMARK 465 TYR A 1079 REMARK 465 GLY A 1080 REMARK 465 ILE A 1081 REMARK 465 PRO A 1082 REMARK 465 THR A 1083 REMARK 465 THR A 1084 REMARK 465 GLU A 1085 REMARK 465 ASN A 1086 REMARK 465 LEU A 1087 REMARK 465 TYR A 1088 REMARK 465 PHE A 1089 REMARK 465 GLN A 1090 REMARK 465 GLY A 1091 REMARK 465 SER A 1092 REMARK 465 HIS A 1124 REMARK 465 GLY A 1125 REMARK 465 SER A 1136 REMARK 465 GLY A 1137 REMARK 465 MET A 1138 REMARK 465 PRO A 1139 REMARK 465 ASN A 1140 REMARK 465 ASP A 1141 REMARK 465 PRO A 1142 REMARK 465 SER A 1143 REMARK 465 ALA A 1280 REMARK 465 SER A 1281 REMARK 465 TYR A 1282 REMARK 465 TYR A 1283 REMARK 465 ARG A 1284 REMARK 465 LYS A 1285 REMARK 465 PRO A 1403 REMARK 465 LEU A 1404 REMARK 465 VAL A 1405 REMARK 465 GLU A 1406 REMARK 465 GLU A 1407 REMARK 465 GLU A 1408 REMARK 465 GLU A 1409 REMARK 465 LYS A 1410 REMARK 465 VAL A 1411 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A1402 CA C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A1248 -7.40 80.91 REMARK 500 ASP A1249 47.78 -150.48 REMARK 500 SER A1332 -7.66 80.49 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2207 DISTANCE = 6.55 ANGSTROMS REMARK 525 HOH A2208 DISTANCE = 9.60 ANGSTROMS REMARK 525 HOH A2209 DISTANCE = 6.69 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE VGH A 9000 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4ANL RELATED DB: PDB REMARK 900 STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE REMARK 900 RELATED ID: 4ANS RELATED DB: PDB REMARK 900 STRUCTURE OF L1196M,G1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE REMARK 900 IN COMPLEX WITH CRIZOTINIB REMARK 900 RELATED ID: 4AOI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-(3-((1H- REMARK 900 PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL )-(1,2,4)TRIAZOLO(4,3-B)(1,2,4) REMARK 900 TRIAZIN-6-YL) BENZONITRILE DBREF 4ANQ A 1093 1411 UNP Q9UM73 ALK_HUMAN 1093 1411 SEQADV 4ANQ MET A 1070 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ ALA A 1071 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1072 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1073 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1074 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1075 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1076 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ HIS A 1077 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ ASP A 1078 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ TYR A 1079 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ GLY A 1080 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ ILE A 1081 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ PRO A 1082 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ THR A 1083 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ THR A 1084 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ GLU A 1085 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ ASN A 1086 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ LEU A 1087 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ TYR A 1088 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ PHE A 1089 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ GLN A 1090 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ GLY A 1091 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ SER A 1092 UNP Q9UM73 EXPRESSION TAG SEQADV 4ANQ ALA A 1269 UNP Q9UM73 GLY 1269 ENGINEERED MUTATION SEQRES 1 A 342 MET ALA HIS HIS HIS HIS HIS HIS ASP TYR GLY ILE PRO SEQRES 2 A 342 THR THR GLU ASN LEU TYR PHE GLN GLY SER ASN PRO ASN SEQRES 3 A 342 TYR CYS PHE ALA GLY LYS THR SER SER ILE SER ASP LEU SEQRES 4 A 342 LYS GLU VAL PRO ARG LYS ASN ILE THR LEU ILE ARG GLY SEQRES 5 A 342 LEU GLY HIS GLY ALA PHE GLY GLU VAL TYR GLU GLY GLN SEQRES 6 A 342 VAL SER GLY MET PRO ASN ASP PRO SER PRO LEU GLN VAL SEQRES 7 A 342 ALA VAL LYS THR LEU PRO GLU VAL CYS SER GLU GLN ASP SEQRES 8 A 342 GLU LEU ASP PHE LEU MET GLU ALA LEU ILE ILE SER LYS SEQRES 9 A 342 PHE ASN HIS GLN ASN ILE VAL ARG CYS ILE GLY VAL SER SEQRES 10 A 342 LEU GLN SER LEU PRO ARG PHE ILE LEU LEU GLU LEU MET SEQRES 11 A 342 ALA GLY GLY ASP LEU LYS SER PHE LEU ARG GLU THR ARG SEQRES 12 A 342 PRO ARG PRO SER GLN PRO SER SER LEU ALA MET LEU ASP SEQRES 13 A 342 LEU LEU HIS VAL ALA ARG ASP ILE ALA CYS GLY CYS GLN SEQRES 14 A 342 TYR LEU GLU GLU ASN HIS PHE ILE HIS ARG ASP ILE ALA SEQRES 15 A 342 ALA ARG ASN CYS LEU LEU THR CYS PRO GLY PRO GLY ARG SEQRES 16 A 342 VAL ALA LYS ILE ALA ASP PHE GLY MET ALA ARG ASP ILE SEQRES 17 A 342 TYR ARG ALA SER TYR TYR ARG LYS GLY GLY CYS ALA MET SEQRES 18 A 342 LEU PRO VAL LYS TRP MET PRO PRO GLU ALA PHE MET GLU SEQRES 19 A 342 GLY ILE PHE THR SER LYS THR ASP THR TRP SER PHE GLY SEQRES 20 A 342 VAL LEU LEU TRP GLU ILE PHE SER LEU GLY TYR MET PRO SEQRES 21 A 342 TYR PRO SER LYS SER ASN GLN GLU VAL LEU GLU PHE VAL SEQRES 22 A 342 THR SER GLY GLY ARG MET ASP PRO PRO LYS ASN CYS PRO SEQRES 23 A 342 GLY PRO VAL TYR ARG ILE MET THR GLN CYS TRP GLN HIS SEQRES 24 A 342 GLN PRO GLU ASP ARG PRO ASN PHE ALA ILE ILE LEU GLU SEQRES 25 A 342 ARG ILE GLU TYR CYS THR GLN ASP PRO ASP VAL ILE ASN SEQRES 26 A 342 THR ALA LEU PRO ILE GLU TYR GLY PRO LEU VAL GLU GLU SEQRES 27 A 342 GLU GLU LYS VAL HET VGH A9000 30 HETNAM VGH 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1- HETNAM 2 VGH PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE HETSYN VGH CRIZOTINIB FORMUL 2 VGH C21 H22 CL2 F N5 O FORMUL 3 HOH *209(H2 O) HELIX 1 1 SER A 1106 LEU A 1108 5 3 HELIX 2 2 PRO A 1112 ILE A 1116 5 5 HELIX 3 3 SER A 1157 PHE A 1174 1 18 HELIX 4 4 LEU A 1204 THR A 1211 1 8 HELIX 5 5 ALA A 1222 ASN A 1243 1 22 HELIX 6 6 ALA A 1251 ARG A 1253 5 3 HELIX 7 7 PHE A 1271 ARG A 1279 1 9 HELIX 8 8 GLY A 1287 LEU A 1291 5 5 HELIX 9 9 PRO A 1292 MET A 1296 5 5 HELIX 10 10 PRO A 1297 GLY A 1304 1 8 HELIX 11 11 THR A 1307 SER A 1324 1 18 HELIX 12 12 SER A 1334 SER A 1344 1 11 HELIX 13 13 PRO A 1355 TRP A 1366 1 12 HELIX 14 14 GLN A 1369 ARG A 1373 5 5 HELIX 15 15 ASN A 1375 ASP A 1389 1 15 HELIX 16 16 ASP A 1389 ASN A 1394 1 6 SHEET 1 AA 2 ASN A1095 PHE A1098 0 SHEET 2 AA 2 LYS A1101 SER A1104 -1 O LYS A1101 N PHE A1098 SHEET 1 AB 5 THR A1117 GLY A1121 0 SHEET 2 AB 5 VAL A1130 GLN A1134 -1 O GLU A1132 N ILE A1119 SHEET 3 AB 5 GLN A1146 THR A1151 -1 O VAL A1147 N GLY A1133 SHEET 4 AB 5 PHE A1193 GLU A1197 -1 O ILE A1194 N LYS A1150 SHEET 5 AB 5 CYS A1182 SER A1186 -1 N ILE A1183 O LEU A1195 SHEET 1 AC 3 GLY A1202 ASP A1203 0 SHEET 2 AC 3 CYS A1255 LEU A1257 -1 N LEU A1257 O GLY A1202 SHEET 3 AC 3 ALA A1266 ILE A1268 -1 O LYS A1267 N LEU A1256 CISPEP 1 LEU A 1190 PRO A 1191 0 -1.96 SITE 1 AC1 13 LEU A1122 ALA A1148 LEU A1196 GLU A1197 SITE 2 AC1 13 MET A1199 ALA A1200 GLY A1202 ARG A1253 SITE 3 AC1 13 ASN A1254 LEU A1256 ALA A1269 ASP A1270 SITE 4 AC1 13 HOH A2124 CRYST1 51.626 57.473 104.617 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019370 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017399 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009559 0.00000